Bupropion Extended-Release Tablets Recalled for Dissolution Failure
Amerisource Health Services is recalling Bupropion Hydrochloride 150mg extended-release tablets nationwide due to dissolution specification failures. The tablets dissolve faster than specified limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with a manufacturing defect affecting drug dissolution and absorption. No illnesses or injuries have been reported, but this represents a risk-of-harm product where efficacy may be compromised.
Plain-English summary
Amerisource Health Services LLC is recalling Bupropion Hydrochloride Extended-release Tablets USP (XL) 150 mg due to a manufacturing defect. The recall covers Lot 1017343, expiration date December 31, 2025, with approximately 2,484 cartons affected and nationwide distribution in the United States.
The product failed dissolution specifications. The tablets dissolve faster than the specified limits, which means they break down more quickly than intended during use.
Patients taking this recalled product should contact their healthcare provider or pharmacist immediately for guidance on their treatment. The medication should not be used. Patients should dispose of the product according to FDA guidance for safe medication disposal.
The recalled product
- Product
- BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE)
- Brand
- BUPROPION HYDROCHLORIDE
- Manufacturer
- Amerisource Health Services LLC
- Category
- Drug — Extended-Release Tablet
- Affected units
- 2,484
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 1017343
- Exp. 12/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUPROPION HYDROCHLORIDE
- ModerateBupropion extended release tablets recalled after failing tablet specifications
FDA (Drugs) · 2025-10-29
- HighFDA recalls Bupropion Hydrochloride tablets for foreign tablet contamination
FDA (Drugs) · 2024-01-17
- ModerateBupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-12-13
- ModerateSun Pharmaceutical Bupropion Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-10-25
- HighBupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2023-05-31
Same manufacturer · Amerisource Health Services LLC
See all →- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighOxycodone blister cards recalled over seals that let tablets fall out
FDA (Drugs) · 2026-02-18
- HighUnit dose prazosin 2 mg cartons recalled over nitrosamine impurity
FDA (Drugs) · 2025-11-05
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17